As you consider the impact of COVID-19, there are several key strategies to help you maintain momentum, assess your risks, and minimize the delays for ongoing, new, and COVID-19-related trials. Our agile and scientific-minded experts have compiled a guide of critical strategies for clinical development success during the COVID-19 era.
Since its onset, COVID-19 has had the industry’s undivided attention. From data integrity to participant recruitment and retention, our industry has temporarily reconsidered long held habits. As the world begins to relax restrictions, what are the lessons learned that can catapult us into the next innovation in trial operations for good?
Supporting COVID-19 trials comes with with aggressive timelines and complexities. Learn how Veristat utilizes best-in-class technologies for COVID-19 trials featuring IBM Clinical Development (ICD) solutions.
Our regulatory experts created this guide to highlight the benefits of, qualifying criteria for, and timing and procedures for six different expedited programs and designations. Click below to learn more.
Veristat was asked to help a current client kick-off a phase I COVID-19 vaccine trial. The sponsor had identified sites and patients. The gating factor was to get the clinical trial database built quickly in order to start enrollment and randomization.
